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Background: Having 90% of patients on antiretroviral therapy
(ART) and achieving an undetectable viral load (VL) is 1 of the
90:90:90 by 2020 targets. In this global analysis, we investigated the
proportions of adult and paediatric patients with VL suppression in
the ﬁrst 3 years after ART initiation.
Methods: Patients from the IeDEA cohorts who initiated ART
between 2010 and 2014 were included. Proportions with VL
suppression (,1000 copies/mL) were estimated using (1) strict
intention to treat (ITT)–loss to follow-up (LTFU) and dead patients
counted as having detectable VL; and (2) modiﬁed ITT—LTFU and
dead patients were excluded. Logistic regression was used to identify
predictors of viral suppression at 1 year after ART initiation using
modiﬁed ITT.
Results: A total of 35,561 adults from 38 sites/16 countries
and 2601 children from 18 sites/6 countries were included.
When comparing strict with modiﬁed ITT methods, the
proportion achieving VL suppression at 3 years from ART
initiation changed from 45.1% to 90.2% in adults, and 60.6% to
80.4% in children. In adults, older age, higher CD4 count pre-
ART, and homosexual/bisexual HIV exposure were associated
with VL suppression. In children, older age and higher CD4
percentage pre-ART showed signiﬁcant associations with
VL suppression.
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Conclusions: Large increases in the proportion of VL suppression
in adults were observed when we excluded those who were LTFU or
had died. The increases were less pronounced in children. Greater
emphasis should be made to minimize LTFU and maximize patient
retention in HIV-infected patients of all age groups.
Key Words: HIV, suppression, paediatrics, adults, IeDEA
(J Acquir Immune Deﬁc Syndr 2017;76:319–329)
INTRODUCTION
Durable virologic suppression is the primary goal of
antiretroviral therapy (ART). Having 90% of patients on ART
with undetectable HIV viral load (VL) is the third “90” for
global programs as part of the 90:90:90 targets.1 Increasingly,
VL testing is offered as part of ART monitoring to conﬁrm
early treatment failure and to indicate second-line treatment
switch to reduce the accumulation of HIV drug resistance
mutations. The World Health Organization (WHO) now
recommends routine VL testing2 as the preferred method
to detect ART failure rather than immunological and
clinical monitoring.
The International Epidemiology Databases to Evaluate
AIDS (IeDEA) global consortium was established by the U.S.
National Institute of Allergy and Infectious Diseases in 2005.
There are 7 regional data centers within IeDEA in North
America (The North American AIDS Cohort Collaboration
on Research and Design, NA-ACCORD), the Caribbean,
Central and South America (CCASAnet), the Asia-Paciﬁc
(AP), and Africa (East Africa, EA; Central Africa, CA; West
Africa, WA; Southern Africa, SnA).3,4 Currently, IeDEA
includes data on more than 1 million people living with HIV/
AIDS. According to individual country assessments5 on HIV
indicators for sites within NA-ACCORD and CCASAnet, the
percentage of patients on ART in the United States was 67%,
whereas the highest was reported for Mexico at 90%. In the
African population, in particular EA and SnA, ART coverage
increased from 24% in 2010 to 54% in 2015, whereas CA and
WA had a lower percentage coverage at 28%. ART usage in
AP doubled from 19% in 2010 to 41% in 2015.6 The
proportion of patients with VL suppression across different
IeDEA regions in recent years, however, remains unclear.
The primary objective of this study was to estimate the
proportions of adult and paediatric patients enrolled in
IeDEA, who achieved undetectable VL in the ﬁrst 3 years
after initiating ART. The secondary objective was to
determine factors associated with VL suppression at 1 year
after ART.
METHODS
Study Population and Inclusion Criteria
Adult and paediatric patients enrolled in IeDEA were
included if they had initiated ART between 2010 and 2014.
Paediatric patients were deﬁned as children and adolescents
aged 18 years and younger when starting ART; adults were
those aged 18 years and older at ART initiation. ART was
deﬁned as 3 or more antiretroviral drugs in a single regimen;
those who started treatment with mono- or dual-drug
regimens were excluded. Sites within each respective partici-
pating region were included if they were conﬁrmed to
perform routine annual VL testing. If no speciﬁc information
was provided regarding VL testing frequency, we performed
a calculation by obtaining the average number of VL tests
for each patient from the regional cohort enrolment date to
the last follow-up date. If the median number of VL tests
per patient per site was above 0.8, that site was included
in the initial data capture. However, only patients with
at least 1 VL test after ART initiation were included in
the analyses.
Definitions
VL suppression was deﬁned as VL ,1000 copies/mL
at 1, 2, and 3 years from ART initiation to be consistent with
the WHO deﬁnition for classifying virological failure.2
Moreover, because of the use of different virological assays
across the regions with varying lower limits of detection, the
use of this threshold of VL ,1000 copies/mL allowed the
inclusion of sites with higher undetectable cutoffs. This
threshold also removed the concern of unnecessarily ex-
cluding patients experiencing transient virological “blips”
and then returning to virologic suppression.”7 The annual
time points reﬂect the WHO recommendations for VL testing
to monitor for treatment failure.8 We have chosen to
include data up to 3 years after ART initiation to minimize
loss to follow-up (LTFU), as patient retention has been shown
to decrease to 65% at 3 years.9 As different sites have
different deﬁnitions of LTFU, patients in this study were
considered to be LTFU according to the LTFU indicator
provided in each regional database. If no LTFU information
was available, patients who were not seen within 6 months10
before the database closing date were considered lost at their
ﬁnal visit date deﬁned as the latest of CD4, VL, or clinic
visit date.
Statistical Analyses
Simple proportions were calculated by percentages.
Two methods were used to estimate proportions of patients
with undetectable VL.
Strict Intention to Treat
Patients who were LTFU or dead were counted as
having detectable VL after their last visit/death date up until 3
years after ART initiation. Patients who were transferred out
were removed from the analyses after their transfer date. The
denominator for each 1-, 2-, and 3- year time point included
patients who had VL testing at that time point and patients
who were LTFU or dead before that time point (counted as
having detectable VL). Patients who did not have VL testing
or transferred out before each time point were not included in
the denominator (Supplemental Digital Content Figs. 1 and 3,
http://links.lww.com/QAI/B64).
Modiﬁed Intention to Treat
The denominator at each time point included patients
who had VL testing at that time point. Patients who did not
have VL testing, or those who were LTFU, dead, or
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transferred out before each time point were not included in the
denominator (Supplemental Digital Content Fig. 2, http://
links.lww.com/QAI/B64).
Factors associated with VL suppression at 1 year, as
deﬁned by the modiﬁed intention-to-treat (ITT) method, were
analyzed using logistic regression methods. We chose to
analyze VL suppression at 1 year to minimize LTFU cases. In
addition, as we included the VL measurement closest to the
annual time point, our analyses would not be biased by how
often VL was assessed. Covariates included were age at ART
initiation, sex, previous AIDS diagnosis, pre-ART CD4 count
or percent, HIV mode of exposure, and region. ART
combinations were not included in the analyses because of
potential collinearity with different regions. For example, we
would expect to see most patients from resource-limited
regions, such as in Asia and Africa, initiating on a nucleoside
reverse transcriptase inhibitors and a non–nucleoside reverse
transcriptase inhibitors combination, whereas protease
inhibitor–based and integrase inhibitor–based regimens
would be most commonly used in developed countries such
as those in NA-ACCORD. All variables were entered in the
multivariable model; no model selection was attempted. P-
values ,0.05 were considered statistically signiﬁcant. Sensi-
tivity analyses were performed using the strict ITT deﬁnition,
as well as using VL failure as the outcome of interest, deﬁned
as VL $1000 copies/mL.
Each regional data center was responsible for ethics
approval, development of data collection systems, extracting
data from their regional database or requesting relevant data
variables from designated programs within their region, and
verifying data quality. The data sets were then centrally
aggregated and analyzed at The Kirby Institute, UNSW
Sydney (the University of New South Wales), Australia, the
regional data center of the IeDEA AP region. All data
management and statistical analyses were performed using
SAS software version 9.4 (SAS Institute Inc., Cary, NC) or
Stata software version 14 (Stata Corp., College Station, TX).
RESULTS
Adults
There were a total of 38 sites from 16 countries: 12
sites/8 countries from AP, 6 sites/5 countries from CCA-
SAnet, 14 sites/2 countries from NA-ACCORD, and 6 sites
from South Africa (SA), a country within the IeDEA SnA
regional cohort that met the eligibility criteria for adult
analyses. Median VL testing frequency for each site ranged
from 0.9 to 4.2 per patient per year. A total of 35,561
patients were included in the analyses: 2121 (6.0%) from
AP; 3404 (9.6%) from CCASAnet; 14,579 (41.0%) from
NA-ACCORD; and 15,457 (43.5%) from SA (Table 1 and
Supplemental Digital Content Table 5, http://links.lww.com/
QAI/B64). Sixty-one percent were men. At ART initiation,
the median age was 37 years [interquartile range (IQR 30–46
years)] and the median CD4 cell count was 218 cells/mL
(IQR: 105-344 cells/mL).
Using the strict ITT method, the overall proportion of
adults with VL suppression at 1 year from ART initiation was
83.0%; 70.0% at 2 years; and 45.1% at 3 years. Figure 1A
shows the proportions of adults with VL suppression
decreasing after 2 years for NA-ACCORD and SA, with
AP maintaining the highest VL suppression over the full 3
years. Using the modiﬁed ITT method where patients who
were LTFU or dead were excluded, of the 35,561 adults
patients, 26,153 (73.5%) had VL testing at 1 year; 13,602
(38.2%) at 2 years; and 4629 (13.0%) at 3 years. Overall, VL
suppression increased to 88.5%, 89.5%, and 90.2% for years
1–3, with all regions showing high proportions above 85% for
all years (Fig. 1B).
Table 2 shows factors associated with VL suppression
at 1 year using the modiﬁed ITT method. The multivariate
results show that after adjustment for all variables, sex was
the only factor showing no association with VL suppression
(P = 0.358). The odds for VL suppression increased with age
25–49 years [odds ratio (OR) = 1.42, 95% conﬁdence interval
(CI): 1.24 to 1.63], and age 50 years and older (OR = 2.20,
95% CI: 1.86 to 2.60), all P , 0.001, compared with age 24
years and younger. Pre-ART CD4 count also showed an
increasing trend: 200–349 cells/mL (OR = 1.60, 95% CI: 1.44
to 1.78), 350–499 cells/mL (OR = 1.73, 95% CI: 1.48 to
2.02), and $500 cells/mL (OR = 1.91, 95% CI: 1.62 to 2.26),
all P , 0.001, compared with CD4 ,200 cells/mL. Patients
TABLE 1. Patient Characteristics
Total Adults:
35,561
Total Children:
2601
Number* (%) Number* (%)
Median age at ART initiation
(yrs)
37 (IQR 30–46) 4.65
(IQR 1.02–9.75)
Sex
Male 21,623 (60.8) 1299 (49.9)
Female 13,935 (39.2) 1302 (50.1)
Unknown 3 (0.0) 0 (0.0)
Previous AIDS-deﬁning illness
No 15,508 (43.6) 164 (6.3)
Yes 2695 (7.6) 52 (2.0)
Unknown 17,358 (48.8) 2385 (91.7)
Median pre-ART CD4 count 218 cells/mL
(IQR 105–344)
15.89%
(IQR 8.70–23.24)
HIV mode of exposure
Homosexual/bisexual 8537 (24.0) 0 (0.0)
Heterosexual 14,216 (40.0) 0 (0.0)
IDU 1639 (4.6) 0 (0.0)
Perinatal 0 (0.0) 2119 (81.5)
Other† 645 (1.8) 190 (7.3)
Unknown 10,524 (29.6) 292 (11.2)
Region
Asia-Paciﬁc 2121 (6.0) 291 (11.2)
Caribbean, Central and South
America
3404 (9.6) 75 (2.9)
North America 14,579 (41.0) 0 (0.0)
South Africa 15,457 (43.5) 2235 (85.9)
*Unless otherwise speciﬁed.
†For children, “Other” includes sexual behaviour (184), sexual abuse (2), blood
transfusion (2), and breastfeeding (2).
IDU, injecting drug users.
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with homosexual/bisexual mode of HIV exposure were more
likely to have VL suppression (OR = 1.66, 95% CI: 1.46 to
1.89, P , 0.001), whereas injecting drug users had reduced
odds compared with heterosexual mode of exposure (OR =
0.69, 95% CI: 0.58 to 0.83, P , 0.001). Having a previous
AIDS-deﬁning illness also negatively affected VL response
(OR = 0.82, 95% CI: 0.71 to 0.95, P = 0.008). Comparison of
different regions showed that when compared with NA-
ACCORD, AP (OR = 2.78, 95% CI: 2.2 to 3.52, P , 0.001)
and CCASAnet (OR = 1.70, 95% CI: 1.45 to 2.00, P ,
0.001) had higher proportions of VL suppression. When AP
was the reference group, patients in CCASAnet (OR = 0.61,
95% CI: 0.47 to 0.79, P , 0.001); NA-ACCORD (OR =
0.36, 95% CI: 0.28 to 0.45, P , 0.001); and SA (OR = 0.37,
95% CI: 0.29 to 0.48, P , 0.001), had smaller proportions of
patients with VL suppression. Additional tests for multi-
collinearity showed that there was no collinearity among the
variables included.
Paediatrics
The paediatric analysis included 18 clinical centers
from 3 IeDEA regions with 2601 children overall: 291
(11.2%) from 10 AP sites/3 countries, 75 (2.9%) from 4
CCASAnet sites/2 countries, and 2235 (85.9%) from 4 sites
in SA (Table 1 and Supplemental Digital Content Table 6,
http://links.lww.com/QAI/B64). Median VL testing fre-
quency for each site ranged from 1.5 to 2.7 per patient per
year. At ART initiation, the median age was 4.7 years (IQR
1.0–9.8). For 1677 children with available data, the median
CD4 percentage was 15.9 (IQR 8.70–23.24) with 477
(18.3%) children having CD4 percentage ,10%. A small
FIGURE 1. Proportion of adults with
viral load (VL) suppression using (A)
strict intention-to-treat and (B)
modified intention-to-treat meth-
ods. CCASAnet, Caribbean, Central,
and South America; VL, viral load.
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proportion (0.2) had experienced WHO clinical stage 4 events
before ART initiation. These baseline patient characteristics
differed between regions. Median CD4 percentage and age
were 12% and 8 years in AP, 23% and 11 years in
CCASAnet, and 16% and 4 years in SA.
Using strict ITT methods as shown in Figure 2A,
a decrease in the proportion of children with VL ,1000
copies/mL over time was seen for CCASAnet (80.3% at year
1, 68.3% at year 2 and 50.0% at year 3) and SA regions
(73.3%–67.5% and 56.7%). Using the modiﬁed ITT
approach, CCASAnet still showed a decline in the proportion
of children with viral suppression from 81.7% to 73.7%, and
69.2% for years 1–3. Overall, during the follow-up period,
69.2%–83.0% of children maintained VL ,1000 copies/mL
(Fig. 2B).
The adjusted statistical analysis (Table 3) identiﬁed
the following baseline characteristics to be associated with
VL suppression at 1 year after ART initiation: age 1.5–4
years (OR = 2.33, 95% CI: 1.73 to 3.14, P , 0.001); 5–9
years (OR = 2.79, 95% CI: 2.06 to 3.78, P , 0.001); 10–14
years (OR = 2.32, 95% CI: 1.70 to 3.16, P , 0.001); and
15–17 years (OR = 2.34, 95% CI: 1.28 to 4.27, P = 0.006)
compared with children younger than 1.5 years (the
reference group); and pre-ART CD4 percentage 15%–24%
(OR = 2.38, 95% CI: 1.67 to 3.41, P , 0.001) and $25%
(OR = 1.81, 95% CI: 1.24 to 2.64, P = 0.002) versus CD4
,10%. Other factors, including sex, WHO clinical stage 4,
mode of exposure, and region were not signiﬁcantly
associated with VL suppression. No collinearity was de-
tected among the variables.
The strict ITT sensitivity analyses (Supplemental
Digital Content Tables 1 and 2, http://links.lww.com/
QAI/B64) showed similar results to the main analyses. In
VL failure analyses (Supplemental Digital Content Tables
3 and 4, http://links.lww.com/QAI/B64), the ORs of the
covariates were simply the reciprocal of the ORs reported
in the main analyses, with the same P-values. This
indicates that the use of logistic regression was appropriate
for both VL suppression and VL failure outcomes in adults
and children.
TABLE 2. Factors Associated With Viral Load Suppression at 1 Year From ART Initiation, Adult Analysis Using Modified Intention-
to-Treat Method (N = 26,153)
Total Patients
VL ,1000
Copies/mL
Univariate Multivariate
OR 95% CI P OR 95% CI P
Age at ART initiation (yrs) ,0.001 ,0.001
18–24 2065 1773 Ref Ref
25–49 19,275 16,974 1.21 1.07 to 1.39 0.004 1.42 1.24 to 1.63 ,0.001
$50 4813 4393 1.72 1.47 to 2.02 ,0.001 2.20 1.86 to 2.60 ,0.001
Sex
Male 16,323 14,565 Ref Ref
Female 9828 8573 0.82 0.76 to 0.89 ,0.001 1.04 0.95 to 1.14 0.358
Unknown 2 2
Previous AIDS-deﬁning illness 0.027 0.008
No 11,027 9705 Ref Ref
Yes 2000 1725 0.85 0.74 to 0.98 0.027 0.82 0.71 to 0.95 0.008
Unknown 13,126 11,710 1.13 1.04 to 1.22 0.003 0.83 0.69 to 0.99 0.036
Pre-ART CD4 count (cells/mL) ,0.001 ,0.001
,200 10,000 8590 Ref Ref
200–349 6241 5661 1.60 1.45 to 1.77 ,0.001 1.60 1.44 to 1.78 ,0.001
350–499 2631 2393 1.65 1.43 to 1.91 ,0.001 1.73 1.48 to 2.02 ,0.001
$500 2363 2160 1.75 1.50 to 2.04 ,0.001 1.91 1.62 to 2.26 ,0.001
Missing 4918 4336 1.22 1.10 to 1.36 ,0.001 1.29 1.16 to 1.44 ,0.001
HIV mode of exposure ,0.001 ,0.001
Homosexual/bisexual 6676 6139 1.73 1.56 to 1.92 ,0.001 1.66 1.46 to 1.89 ,0.001
Heterosexual 10,403 9036 Ref Ref
IDU 1229 1017 0.73 0.62 to 0.85 ,0.001 0.69 0.58 to 0.83 ,0.001
Other 504 449 1.24 0.93 to 1.64 0.148 1.10 0.82 to 1.48 0.534
Unknown 7341 6499 1.17 1.07 to 1.28 0.001 1.23 1.12 to 1.36 ,0.001
Region ,0.001 ,0.001
Asia-Paciﬁc 1806 1719 0.38 0.31 to 0.48 ,0.001 2.78 2.20 to 3.52 ,0.001
Caribbean, Central and South America 2777 2546 0.68 0.59 to 0.79 ,0.001 1.70 1.45 to 2.00 ,0.001
North America 10,970 9685 Ref Ref
South Africa 10,600 9190 1.16 1.07 to 1.25 ,0.001 1.03 0.85 to 1.25 0.767
Values in bold represent signiﬁcant covariates in the adjusted model.
IDU, injecting drug use.
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DISCUSSION
Our study included data from 4 IeDEA regions
covering 35,561 patients from 38 adult sites and 2601 patients
from 24 paediatric sites who initiated ART between 2010 and
2014. Using the modiﬁed ITT approach that excludes LTFU
and those who died, the proportions of patients with VL
suppression was 90% for adults and 80% for children at 3
years. However, when the strict ITT approach was used,
including LTFU and deceased patients and categorizing them
as having detectable VL, these estimates decreased to 45% in
adults and 61% in children. In adults, older age, higher
pre-ART CD4 count, homosexual/bisexual and other modes
of HIV exposure were associated with a better chance of
achieving VL suppression at 1 year from ART initiation.
Children older than 1.5 years and CD4 $15% were
associated with a higher chance of achieving VL suppression.
Adults from the AP region performed signiﬁcantly better than
other regions. In children, VL suppression at 1 year did not
differ signiﬁcantly between regions.
Patients included in this study were those from sites that
offered routine annual VL testing. Many resource-limited
countries throughout the world currently do not offer routine
VL tests for the detection of HIV treatment failure. For
example, all sites within the WA, CA, and EA IeDEA regions
and countries within the SnA IeDEA region outside SA did
not have annual VL testing for the 2010–2014 time period.
Some countries in the AP region, including Cambodia and
Vietnam, also did not perform routine VL testing. The WHO2
guidelines have recently recommended that VL testing be the
preferred method of detecting treatment failure, and many
countries have adopted this recommendation and are
scaling-up their VL monitoring capacity.11,12 Studies have
FIGURE 2. Proportion of paediatric
patients with viral load (VL) suppres-
sion using (A) strict intention-to-treat
and (B) modified intention-to-treat
methods. CCASAnet, Caribbean,
Central, and South America; VL, viral
load.
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shown that the WHO’s immunologic and clinical failure
criteria have performed poorly in predicting virological
treatment failure leading to unnecessary switch to second-line
ART during periods of VL suppression, or delayed switch
because of the misclassiﬁcation of treatment failure.13–15 Using
CD4 monitoring in the presence of HIV drug resistance,
mutations during periods of viraemia may also lead to delayed
ART switches compared with VL monitoring alone.16 Delayed
second-line ART switch can lead to the accumulation of drug-
resistant mutations,17,18 which can compromise treatment
options for second-line therapy, particularly in resource-
limited countries. In addition, low positive predictive value
of current immunological criteria may result in increased costs
because of unnecessary switches to second-line therapy in
people with adequate VL suppression.14 Unfortunately, some
countries that do not yet offer VL monitoring continue to refer
to CD4 measurements and clinical monitoring in the assess-
ment of HIV treatment outcomes.
The overall high proportions of VL suppression under
the modiﬁed ITT analyses indicate that patients who are
followed-up and retained in care have a good response to
treatment. This is in contrast to the decrease in the proportion
of adults and children achieving VL suppression when LTFU
and dead patients were included as being detectable under
strict ITT methods. The decrease in the proportion of patients
with VL suppression was less pronounced in children. When
compared with adults, children had higher rates of suppres-
sion when we considered LTFU and death as detectable. This
might be explained by a lower rate of LTFU in children (6%)
compared with adults (12%) in this study. The decrease in VL
suppression when patients who were LTFU or dead were
assumed to have detectable viraemia has also been reported in
another study,19 which suggests the importance of retention in
HIV care. Mortality rates were often found to be higher in
children and adults who were LTFU or transferred out
compared with patients who were retained in care.20,21 An
Australian study, however, showed no association between
LTFU and mortality, possibly because of unreported reen-
gagement into care.22
The multivariate analyses in this study indicate that the
adult AP cohort has performed signiﬁcantly better than NA-
ACCORD as well as other cohorts, although proportions of
VL suppression were above 85% for all regions. These results
most likely reﬂect the patient recruitment process within AP.
Sites in AP are urban referral centres and patients were
recruited based on the likelihood of remaining in care.23
TABLE 3. Factors Associated With Viral Suppression at 1 Year From ART Initiation, Paediatric Analysis Using Modified Intention to
Treat Method (N = 1968)
Total Patients
VL ,1000
Copies/mL
Univariate Multivariate
OR 95% CI P OR 95% CI P
Age at ART initiation (yrs) ,0.001 ,0.001
,1.5 569 364 Ref Ref
1.5–4 441 355 2.32 1.74 to 3.11 ,0.001 2.33 1.73 to 3.14 ,0.001
5–9 492 405 2.62 1.97 to 3.50 ,0.001 2.79 2.06 to 3.78 ,0.001
10–14 395 311 2.09 1.55 to 2.80 ,0.001 2.32 1.70 to 3.16 ,0.001
15–17 71 56 2.10 1.16 to 3.81 0.014 2.34 1.28 to 4.27 0.006
Sex
Male 977 731 Ref Ref
Female 991 760 1.11 0.90 to 1.36 0.333 1.11 0.89 to 1.37 0.350
Previous AIDS-deﬁning illness 0.199 0.613
No 127 111 Ref Ref
Yes 38 30 0.54 0.21 to 1.38 0.199 0.78 0.30 to 2.03 0.613
Unknown 1803 1350 0.43 0.25 to 0.73 0.002 0.53 0.31 to 0.92 0.024
Pre-ART CD4 (%) 0.021 ,0.001
,10 396 291 Ref Ref
10–14 228 175 1.19 0.81 to 1.74 0.366 1.43 0.97 to 2.11 0.074
15–24 419 356 2.04 1.44 to 2.89 ,0.001 2.38 1.67 to 3.41 ,0.001
$25 293 226 1.22 0.86 to 1.73 0.274 1.81 1.24 to 2.64 0.002
Missing 632 443 0.85 0.64 to 1.12 0.242 1.11 0.83 to 1.49 0.491
HIV mode of exposure 0.238 0.164
Perinatal 1592 1197 0.76 0.49 to 1.19 0.238 0.72 0.46 to 1.14 0.164
Sexual behaviour 129 103 Ref Ref
Other/Unknown 247 191 0.86 0.51 to 1.45 0.575 0.86 0.50 to 1.48 0.591
Region 0.083 0.384
Asia-Paciﬁc 229 185 Ref Ref
Caribbean, Central and South America 60 49 1.06 0.51 to 2.20 0.877 1.02 0.47 to 2.21 0.959
South Africa 1679 1257 0.71 0.50 to 1.00 0.051 0.80 0.56 to 1.14 0.217
Values in bold represent signiﬁcant covariates in the adjusted model.
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These results therefore do not represent the general HIV-
infected population in Asia, and should be interpreted with
caution. In contrast, for children the chance of VL suppres-
sion did not differ across regions which may indicate less
between-region heterogeneity and less variations in both
patient-level and site-speciﬁc factors. High clinical resources
and access to paediatric antiretroviral formulations were
reported in a survey of paediatric HIV programmatic and
clinical management practices in Asia and sub-Saharan
Africa.24
The association between older age and higher pre-ART
CD4 count with VL suppression, and the increased risk of VL
failure in patients with injecting drug users mode of exposure
and those who had a previous AIDS-deﬁning illness in adults
are consistent with other published literature.19,25–27 Although
homosexual mode of exposure is often associated with lower
adherence levels leading to poorer treatment outcomes,28 the
positive effect of this transmission group could possibly be
explained by better ART adherence levels reported in some
patients.29–31 We found that children who initiated ART when
CD4 .10% and those who started at 1.5 years of age were
more likely to achieve VL suppression. This may reﬂect the
impact of early access to ART and higher baseline level of
RNA in infants and young children. An early study conducted
in America found that infants whose disease progressed
rapidly have high numbers of HIV-1 RNA copies during
the ﬁrst 24 months of life.32 The association between high
baseline VL (.1 million copies/mL) and VL failure has been
also reported by a more recent study conducted in children in
SA.33 In addition, adherence issues related to taste and
formulation, dosing and/or high pharmacokinetic variability
of drugs might adversely affect virological response and
contribute to poorer responses in younger children.34
Our study has several limitations including the classi-
ﬁcation of LTFU and dead patients as having detectable VL.
Classifying dead patients as virological failure is debatable in
terms of 90:90:90 and treatment as prevention. However, we
have used this deﬁnition to be consistent with that used in
clinical trials where LTFU and dead patients would generally
be classiﬁed as “failed.” It is also consistent with a strict ITT
approach which includes all patients. Known transferred
cases were excluded from the calculations, but there may be
instances where patients have self-transferred without the
knowledge of the treating physician. Patients in follow-up
without VL testing were also not included in our analyses.
This could be considered a potential bias as targeted VL
testing to conﬁrm treatment failure often occurs in resource-
limited settings. However, as our study only included sites
with annual VL testing, we assume that the bias caused by
targeted VL testing would be minimized. Last, the lack of
data completeness and heterogeneity of treatment approaches
and settings are another concern when analyzing large
collaborative data set. There may be discrepancies between
the actual last follow-up date and the ﬁnal visit date calculated
using our deﬁnition which could lead to misclassiﬁcations of
LTFU patients. Furthermore, 86% of children in this study are
from SA, therefore the generalizability of our paediatric
ﬁndings is limited. Data on ART adherence and factors
related to ART adherence such as disclosure and orphan
status in children were not available in our data set and
therefore were not included in the multivariate analyses. As
adherence level is a known predictor of virological out-
comes35 and disclosure in children is associated with ART
adherence,36 our analysis results should be interpreted with
this in mind.
CONCLUSIONS
This multiregional collaborative study showed that
a high level of VL suppression can be achieved among
children and adults receiving ART in resource-limited
settings. Our ﬁndings highlight that even for those retained
in care, achieving 90:90:90 for children may be more
challenging. Sustainable approaches are needed to ensure
optimal clinical outcomes and to minimize LTFU and
increase patient retention.
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